Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
Puma Biotechnology Surging
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
What Happened To Puma Biotechnology?
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology falls more than 20%
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Articles with Puma Biotechnology
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology
Puma Bio FDA Advisory Panel Live Blog - TheStreet
